Thomas Hitchcock

Dr. Thomas Hitchcock serves as the Chief Science Officer for Crown Laboratories and oversees Clinical Development, Medical Affairs and Research & Development for Crown and its subsidiaries. He was also the Founder of Xycrobe Therapeutics Inc. and served as its Chief Executive Officer until acquired by Crown in 2019. Additionally, he was the Acting Chief Scientific Officer overseeing Clinical & Medical Affairs at Bellus Medical from its inception in 2013 up to the acquisition by Crown Laboratories. Dr. Hitchcock also currently serves as an adjunct faculty member of the East Tennessee State University Department of Biomedical Science.

Previous to his work in the industry, Dr. Hitchcock performed research at Weill Cornell Medical College, where he studied multiple myeloma genetics. He also performed post-doctoral research in tissue engineering and regenerative medicine at Duke University and Yale University. Following his post-doctoral studies, Dr. Hitchcock began working in the field of dermatology at emerging companies such as Ulthera, Inc. (acquired by Merz in 2014), as well as consultancy for companies such as Boehringer Ingelheim and Bayer.

Dr. Hitchcock has more than 15 years of research experience, including Basic Science, Proof-of-Concept, Pre-Clinical and Clinical Research across several therapeutic areas such as Cardiology, Oncology, Gene Therapy, Plastic/Facial Plastic Surgery, Dermatology and Aesthetic Medicine. Dr. Hitchcock earned his Ph.D. in Genetics from Clemson University and completed post-doctoral trainings at Duke University and Yale University in Biomedical Engineering, Vascular Biology and Therapeutics.